The last 1/4ly did state “research and development expenditures in the December quarter relate to three clinical trials which have completed expensive clinical stage. Hence, future expenditures will be lower.” We don’t know however the payment terms for CRO and what % was still to be completed end December. However R&D expense in December 1/4ly was historically very high.
$30 Billion Deal, page-4687
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
0.005(11.1%) |
Mkt cap ! $45.11M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 5.2¢ | 4.6¢ | $42.25K | 871.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 155000 | 2 |
View Market Depth
| Last trade - 15.51pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.0¢ |
Change
0.005 ( 8.70 %) |
||||
| Open | High | Low | Volume | ||
| 4.6¢ | 5.1¢ | 4.6¢ | 221683 | ||
| Last updated 15.49pm 14/06/2024 ? | |||||
| BIT (ASX) Chart |